6533b825fe1ef96bd1281ec3

RESEARCH PRODUCT

Host-directed therapies for COVID-19

Renata RamalhoFu-sheng WangMarkus MaeurerAlimuddin Zumla

subject

InflammationPulmonary and Respiratory Medicine2019-20 coronavirus outbreakCoronavirus disease 2019 (COVID-19)SARS-CoV-2medicine.drug_classbusiness.industryMesenchymal stem cellCOVID-19InflammationLong term disabilityMesenchymal Stem Cell TransplantationBioinformaticsMonoclonal antibodymedicineHumansImmunologic FactorsIn patientMolecular Targeted Therapymedicine.symptombusinessCause of death

description

Purpose of review Severe acute respiratory syndrome coronavirus-2-induced hyperinflammation is a major cause of death or end-organ dysfunction in COVID-19 patients. We review adjunct host-directed therapies (HDTs) for COVID-19 management. Recent findings The use of umbilical cord-derived mesenchymal stem cells as HDT for COVID-19 has been shown to be safe in phase 1 and 2 trials. Trials of anti-interleukin-6 receptor antibodies show promising mortality benefit in hospitalized COVID-19 patients. Repurposed drugs and monoclonal antibodies targeting specific cytokines acting on different aspects of the pro- and anti-inflammatory cascades are under evaluation. Summary A range of HDTs shows promise for reducing mortality and improving long term disability in patients with severe COVID-19, and require evaluation in randomized, controlled trials.

yearjournalcountryeditionlanguage
2021-02-26Current Opinion in Pulmonary Medicine
https://doi.org/10.1097/mcp.0000000000000769